In this paper, we demonstrated that this novel Btk inhibitor PLS-123 exhibited more potent anti-proliferative effects than ibrutinib in multiple cellular and in vivo preclinical models of B-cell lineage malignancy, including 14 kinds of cell lines, patients' primary tumor cells and mouse xenograft model. Here, BTK is linked to neoplasm.